Related references
Note: Only part of the references are listed.CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner
Hadjer Abdelouahab et al.
ONCOTARGET (2017)
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
Alexander Scholz et al.
EMBO MOLECULAR MEDICINE (2016)
Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas
Saori Okamoto et al.
BRAIN TUMOR PATHOLOGY (2016)
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
Yuji Piao et al.
NEURO-ONCOLOGY (2016)
Histopathological investigation of glioblastomas resected under bevacizumab treatment
Ryota Tamura et al.
ONCOTARGET (2016)
Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine
Sang-Soo Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models
Giovanni Luca Gravina et al.
BMC CANCER (2015)
Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy
Meng Zhang et al.
BRAIN TUMOR PATHOLOGY (2015)
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner
Kien Pham et al.
CANCER LETTERS (2015)
Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma
Seunggu J. Han et al.
NEUROSURGERY (2015)
miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal
Valentina Lulli et al.
ONCOTARGET (2015)
Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy
Hui Xu et al.
ONCOTARGET (2015)
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway
Emeline Tabouret et al.
ONCOTARGET (2015)
Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme
Wonyoung Kang et al.
ONCOTARGET (2015)
Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models
Giovanni Luca Gravina et al.
PROSTATE (2014)
Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma
Amy Barone et al.
ONCOTARGET (2014)
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes
Konrad Gabrusiewicz et al.
ONCOTARGET (2014)
An Orthotopic Glioblastoma Mouse Model Maintaining Brain Parenchymal Physical Constraints and Suitable for Intravital Two-photon Microscopy
Clement Ricard et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)
Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy
Gregory J. Baker et al.
NEOPLASIA (2014)
Bone Marrow-Derived Microglia Infiltrate into the Paraventricular Nucleus of Chronic Psychological Stress-Loaded Mice
Koji Ataka et al.
PLOS ONE (2013)
Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity
Monica Gatti et al.
TOXICOLOGY (2013)
Effects of Tyrosine Kinase Inhibitors and CXCR4 Antagonist on Tumor Growth and Angiogenesis in Rat Glioma Model: MRI and Protein Analysis Study
Meser M. Ali et al.
TRANSLATIONAL ONCOLOGY (2013)
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan V. Lu et al.
CANCER CELL (2012)
Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma
Yu-Long Hu et al.
CANCER RESEARCH (2012)
Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy
Michael Delay et al.
CLINICAL CANCER RESEARCH (2012)
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma
Randy D'Amico et al.
NEUROLOGICAL RESEARCH (2012)
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Dan G. Duda et al.
CLINICAL CANCER RESEARCH (2011)
VEGFR2 Expression and TGF-beta Signaling in Initial and Recurrent High-Grade Human Glioma
Elizabeth A. Kuczynski et al.
ONCOLOGY (2011)
Antitumor Effect of NK012, a 7-Ethyl-10-Hydroxycamptothecin-Incorporating Polymeric Micelle, on U87MG Orthotopic Glioblastoma in Mice Compared with Irinotecan Hydrochloride in Combination with Bevacizumab
Jun-ichiro Kuroda et al.
CLINICAL CANCER RESEARCH (2010)
Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
Lei Xu et al.
CANCER RESEARCH (2009)
Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy
Agda K. Lucio-Eterovic et al.
CLINICAL CANCER RESEARCH (2009)
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models
Claudio Festuccia et al.
ENDOCRINE-RELATED CANCER (2009)
Discovery of Novel Non-Cyclam Polynitrogenated CXCR4 Coreceptor Inhibitors
Sofia Pettersson et al.
CHEMMEDCHEM (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model
Veronique Mathieu et al.
NEOPLASIA (2008)
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
Sophie de Boueard et al.
NEURO-ONCOLOGY (2007)
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
Grazia Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Tumor models for efficacy determination
Beverly A. Teicher
MOLECULAR CANCER THERAPEUTICS (2006)
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo
F Bruzzese et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
